Nutrichem(BJ:833819)2023-10-26 16:00Financial Performance - Operating revenue for the first nine months of 2023 was CNY 4,395,196,061.07, a decrease of 30.69% from CNY 6,341,279,914.26 in the same period of 2022[10] - Net profit attributable to shareholders for the first nine months of 2023 was CNY 153,501,845.12, down 83.32% from CNY 920,126,712.44 in the previous year[10] - Basic earnings per share for the first nine months of 2023 was CNY 0.13, a decline of 82.67% compared to CNY 0.75 in the same period last year[10] - Total operating revenue for the first nine months of 2023 was CNY 4,395,196,061.07, a decrease of 30.7% compared to CNY 6,341,279,914.26 in the same period of 2022[45] - Net profit for the first nine months of 2023 was CNY 146,099,771.33, a decline of 84.2% compared to CNY 922,731,432.90 in 2022[46] - The company reported a total comprehensive income of CNY 205,995,719.47 for the first nine months of 2023, down from CNY 1,095,638,779.43 in 2022[47] Cash Flow - The net cash flow from operating activities for the first nine months of 2023 was negative CNY 64,208,298.91, a decrease of 104.87% from CNY 1,317,190,376.09 in the previous year[10] - Cash inflow from operating activities decreased to 4,156,720,102.99 from 6,264,814,719.37, a decline of approximately 33.5%[54] - The company’s cash flow from operating activities was negative, indicating potential liquidity challenges moving forward[54] - Cash inflow from investment activities was 484,208,833.32, up from 112,106,153.36, indicating a significant increase[54] - Cash inflow from financing activities increased to 3,965,761,552.79 from 3,490,048,417.37, reflecting a growth of approximately 13.6%[55] Assets and Liabilities - Total assets as of September 30, 2023, reached CNY 12,705,778,025.62, an increase of 1.27% compared to CNY 12,546,601,755.66 at the end of 2022[10] - The company's debt-to-asset ratio (consolidated) increased to 53.58% from 52.72% at the end of 2022[10] - Long-term borrowings increased by 262.17% to CNY 688,510,036.12 due to additional bank financing for project construction[13] - Total liabilities rose to ¥6,808,280,830.05 from ¥6,614,545,392.17, marking an increase of about 2.93%[37] - The company's total liabilities increased to CNY 3,089,751,787.82 in 2023 from CNY 2,859,299,096.25 in 2022, reflecting a growth of 8.0%[43] Shareholder Information - The total number of ordinary shares at the end of the period was 1,225,800,000, with 98.55% being unrestricted shares[19] - The largest shareholder, Huabang Life Health Co., Ltd., holds 46.45% of the shares, increasing from 46.28%[21] - The number of shareholders holding more than 5% of shares is 10, with a total holding of 71.11%[22] Investment and Expenses - Investment income dropped by 98.33% to CNY 6,599,904.69, significantly impacted by the poor performance of major joint ventures[14] - Research and development expenses for the first nine months of 2023 were CNY 140,297,646.87, a decrease of 15.7% compared to CNY 166,463,104.14 in 2022[45] - The company reported a significant increase in financial expenses by 1,669.86% to CNY 87,837,820.98, primarily due to exchange rate fluctuations[14] - The company’s financial expenses for the first nine months of 2023 were CNY 87,837,820.98, compared to a financial income of CNY 5,595,252.62 in 2022[45] Other Financial Information - Government subsidies recognized in the current period amounted to 11,274,064.00, closely related to normal business operations[16] - The company reported a loss of 4,997,722.77 from fair value changes in financial assets and liabilities[16] - The total value of restricted assets is 1,345,454,926.00, accounting for 10.60% of total assets[30] - The company has no significant litigation or arbitration matters reported during the period[27] - The company has complied with all disclosed commitments and obligations during the reporting period[29]